<DOC>
	<DOCNO>NCT02516657</DOCNO>
	<brief_summary>The purpose study study effect liraglutide , glucagon-like peptide agonist , post-meal blood glucose concentration , glucagon level , mean weekly blood sugar , insulin dos adolescent Type 1 diabetes . Type 1 diabetes autoimmune disease usually diagnose age 20 . Individuals disease completely dependent insulin survival . While significant advance make technological support improve diabetes control , insulin remain effective treatment Type 1 diabetes . Liraglutide long-acting glucagon-like peptide-1 analog . This drug approve treatment Type 2 diabetes adults . This study test effect liraglutide blood sugar control adolescents Type 1 diabetes .</brief_summary>
	<brief_title>Liraglutide Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosis Type 1 Diabetes Mellitus great 1 year Insulin regimen continuous subcutaneous insulin infusion continuous glucose monitoring device HbA1c &lt; 10 % Previous exposure liraglutide History abdominal surgery Gastrointestinal reflux disease History acute chronic pancreatitis History alcohol abuse unwillingness abstain alcohol study History thyroid cancer Family history Multiple Endocrine Neoplasia 2B syndrome Pregnant/breastfeeding females Individuals antibodynegative insulin require diabetes consistent Monogenic Diabetes Youth Individuals steroid induce cystic fibrosis relate diabetes</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>